From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

Blinatumomab Leads to High Remission Rate in Infants With Persistent MRD-Positive ALL

Treatment with the bispecific CD19/CD3 antibody blinatumomab induced molecular remissions in most infants with persistent measurable residual disease (MRD)–positive acute lymphocytic leukemia (ALL), according...
WIB_icon

Avadomide Shows Promising Clinical Activity and Tolerability in Relapsed/Refractory DLBCL

Avadomide monotherapy demonstrated preliminary clinical efficacy in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), according to results from a phase I...
WIB_icon

Peripherally Inserted Central Catheters Sharply Increase Risk of Childhood VTE Events

In children who received central venous catheters, peripherally inserted central catheters (PICCs) appear to be associated with a higher risk of venous thromboembolism (VTE),...

The MAGIC Marker: Measurements of Two Serum Biomarkers Predict GVHD Treatment Response

Measuring damage to crypts in the gastrointestinal tract during graft-versus-host disease (GVHD) via the Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm probability (MAP)...

Early Peripheral Blast Cell Clearance Predicts Response to Induction Chemotherapy in Acute Myeloid Leukemia

Early peripheral blast cell clearance (PBC) assessed by leukocyte differential is well established as a predictor of leukemia induction outcome, but measuring PBC by...
WIB_icon

Can a CAR T-Cell “Cocktail” Overcome Antigen Escape?

A sequential infusion of 2 third-generation chimeric antigen receptor (CAR) T cells targeting CD19 and CD22, respectively, was associated with a high response rate...
WIB_icon

Novel JAK2 Insertion/Deletion Mutation Associated With Unique MPN Overlap Syndrome

In a small study of patients with myeloproliferative neoplasms (MPNs), a novel JAK2 insertion/deletion mutation, which the investigators termed JAK2ex13InDel, was found to drive...

Defining the Goals of Venetoclax Treatment in Relapsed/Refractory CLL

Achieving undetectable measurable residual disease (MRD) predicts a better clinical outcome in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who are treated with venetoclax,...

Shifting From Eligibility to Optimization of Transplant in Older Adults With Hematologic Malignancies

In an article published in Blood Advances, researchers from the University of Chicago reported efforts to optimize outcomes after hematopoietic cell transplantation (HCT) in...
WIB_icon

Updates From ECHELON-1: Brentuximab Vedotin Provides Durable Efficacy in Hodgkin Lymphoma

Previously reported results from the phase III ECHELON-1 trial suggested that replacing bleomycin with brentuximab vedotin in the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)...
Advertisement

Current Issue

March 2020, Volume 6, Issue 4

This issue looks at how cost-effective analyses are used to inform health-care decisions, explains the latest maintenance of certification requirements, and more.